Co-founder, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Kamil Ali-Jackson, Esquire, co-founded Aclaris and has served as Chief Legal Officer since its inception in 2012.
With more than 35 years of experience in the legal and pharmaceutical industries, Kamil also serves as Chief Compliance Officer and Corporate Secretary of Aclaris. In addition, she co-founded NeXeption, LLC, a biopharmaceutical assets management company, and its affiliated companies, and previously served as the Chief Legal Officer from 2012 to 2020. Previously, she served as legal counsel and as a licensing business executive for a number of pharmaceutical companies, including Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., and Endo Pharmaceuticals, Inc.
Kamil received a Juris Doctorate from Harvard Law School and Bachelor of Arts in politics from Princeton University. She was a 2011 Philadelphia Business Journal Woman of Distinction winner and a 2015 Pepper Hamilton, LLP remarkable alumna. Kamil currently serves on the board of directors, audit committee, compensation committee and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly held immuno-oncology company, and as an independent director of Moda Operandi, a privately held online luxury retail company.
Kamil has also served on several nonprofit boards and currently serves on the board of trustees of Rosemont College, a private liberal arts college in Pennsylvania.
What is Kamil Ali-Jackson's net worth?
The estimated net worth of Kamil Ali-Jackson is at least $146,635.20 as of June 3rd, 2021. Ms. Ali-Jackson owns 122,196 shares of Aclaris Therapeutics stock worth more than $146,635 as of April 26th. This net worth evaluation does not reflect any other assets that Ms. Ali-Jackson may own. Learn More about Kamil Ali-Jackson's net worth.
How do I contact Kamil Ali-Jackson?
Has Kamil Ali-Jackson been buying or selling shares of Aclaris Therapeutics?
Kamil Ali-Jackson has not been actively trading shares of Aclaris Therapeutics within the last three months. Most recently, Kamil Ali-Jackson sold 9,492 shares of the business's stock in a transaction on Thursday, June 3rd. The shares were sold at an average price of $21.96, for a transaction totalling $208,444.32. Following the completion of the sale, the insider now directly owns 122,196 shares of the company's stock, valued at $2,683,424.16. Learn More on Kamil Ali-Jackson's trading history.
Who are Aclaris Therapeutics' active insiders?
Are insiders buying or selling shares of Aclaris Therapeutics?
During the last year, Aclaris Therapeutics insiders bought shares 1 times. They purchased a total of 14,705 shares worth more than $99,994.00. During the last year, insiders at the biotechnology company sold shares 3 times. They sold a total of 18,000 shares worth more than $136,080.00. The most recent insider tranaction occured on October, 23rd when insider Joseph Monahan sold 6,000 shares worth more than $30,480.00. Insiders at Aclaris Therapeutics own 5.5% of the company.
Learn More about insider trades at Aclaris Therapeutics. Information on this page was last updated on 10/23/2023.
